#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteopetrosis Short stature Niemann-Pick disease Alveolar proteinosis Myasthenia gravis Chronic cutaneous lupus erythematosus Exudative retinopathy Myelofibrosis Glomerulonephritis minimal lesion Gestational trophoblastic tumour Marginal zone lymphoma Demyelination Scedosporium infection Chondrosarcoma metastatic Familial amyotrophic lateral sclerosis More trials…

    Learn about Rare Diseases

    Synovial sarcoma recurrent – Basic Information Skin angiosarcoma – Life with Disease Mastocytosis – Basic Information Primary biliary cholangitis – Diagnostics Hereditary hypophosphataemic rickets – Life with Disease Systemic mastocytosis – Trials in Disease Rhabdoid tumour Mucopolysaccharidosis III – Life with Disease Rhabdomyosarcoma – Life with Disease MELAS syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Alpelisib Potassium Tepotinib Stiripentol Gremubamab Nortriptyline Dabigatran Alirocumab Paracetamol Ublituximab Landiolol Hydrochloride Cortisone Acetate Phenylbutyrate Macrogol 3350 Ofloxacin Hydrochloride Durvalumab GSKVX000000017986 Viltolarsen Calcium Pantothenate Bp JX10 More therapies…

    Learn about Your Condition

    Chondropathy Actinic keratosis Penile squamous cell carcinoma Ependymoma malignant Critical illness Addison's disease Thromboembolectomy Juvenile idiopathic arthritis Mumps Infant sedation Cholecystitis acute Methylmalonic acidaemia Pyrexia Transient ischaemic attack Ovarian cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General University Hospital Of Larissa

General University Hospital Of Larissa

P. O. Box 1425, Larissa, 411 10, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Aflibercept
    • Bevacizumab
    Austria Belgium Czechia Denmark Finland France +9

  • Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Small cell lung cancer limited stage
    Investigated Drugs:
    • Olaparib
    • Carboplatin
    • Cisplatin
    Belgium Bulgaria Estonia France Greece Hungary +5

  • Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    Bulgaria Croatia Czechia France Germany Greece +6

  • Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • SIGVOTATUG VEDOTIN
    • Docetaxel
    Austria Belgium Czechia France Germany Greece +7

  • Study on Andexanet Alfa for Patients on Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Needing Urgent Surgery to Reduce Bleeding Risk

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Aminocaproic Acid
    • Blood And Related Products
    • Etamsylate
    Austria Belgium Bulgaria Czechia Denmark Estonia +13

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Leuprorelin
    • Abemaciclib
    • Giredestrant
    Austria Belgium Finland France Germany Greece +7

  • Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Durvalumab
    Belgium France Germany Greece Ireland Italy +5

  • Study on the Effects of Enpatoran for Patients with Dermatomyositis and Polymyositis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Dermatomyositis
    • Polymyositis
    Investigated Drugs:
    • Enpatoran
    Czechia Greece Italy Poland Spain Sweden

  • Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

    Not recruiting

    3 1
    Investigated Diseases:
    • Heart failure with reduced ejection fraction
    Investigated Drugs:
    • Vericiguat
    Austria Czechia Denmark France Germany Greece +6

  • Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Finland France Germany Greece +7
Previous Page
1 … 17 18 19 20 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!